Skip to Content

Reyvow (lasmiditan) Disease Interactions

There are 4 disease interactions with Reyvow (lasmiditan):

Major

Lasmiditan (Includes Reyvow) ↔ hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The use of lasmiditan is not recommended in patients with severe hepatic impairment. No dosage adjustment is needed for patients with mild or moderate hepatic impairment.

Moderate

Lasmiditan (Includes Reyvow) ↔ CNS depression

Moderate Potential Hazard, Moderate plausibility. Applies to: Altered Consciousness, Alcoholism

The use of lasmiditan may cause central nervous system (CNS) depression, including dizziness and sedation. Because of the potential for lasmiditan to cause sedation, other cognitive or neuropsychiatric adverse reactions, and driving impairment, this agent should be used with caution if used in combination with alcohol or other CNS depressants. It is recommended to evaluate patients for risk of CNS depression and patients should be warned against engaging in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after lasmiditan is taken. Patients who cannot follow this recommendation should not take lasmiditan.

Moderate

Lasmiditan (Includes Reyvow) ↔ drug abuse

Moderate Potential Hazard, Moderate plausibility. Applies to: Drug Abuse/Dependence

The use of lasmiditan has the potential to cause abuse. It is recommended to evaluate patients for risk of drug abuse and observe them for signs of lasmiditan misuse or abuse. Drug dependence was not observed in healthy subjects following abrupt cessation after 7 daily doses of lasmiditan 200 mg or 400 mg.

Moderate

Lasmiditan (Includes Reyvow) ↔ serotonin syndrome

Moderate Potential Hazard, Moderate plausibility. Applies to: CNS Disorder

The use of lasmiditan has been associated with reactions consistent with serotonin syndrome. Serotonin syndrome may also occur with lasmiditan during coadministration with serotonergic drugs. The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. It is recommended to discontinue therapy if serotonin syndrome is suspected.

Reyvow (lasmiditan) drug interactions

There are 435 drug interactions with Reyvow (lasmiditan)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.